KRAS and renal cell carcinoma: FKBP10 was also found to be upregulated in KRAS-mutant lung adenocarcinoma, renal cell carcinoma, and gastric cancer, and knockdown of FKBP10 is sufficient to hinder proliferation of tumor cells growth [18–20].